Assessment of high-priced systemic antifungal prescriptions.

[1]  S. Bailly,et al.  Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study , 2016, Annals of Intensive Care.

[2]  S. Bailly,et al.  Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data , 2015, Intensive Care Medicine.

[3]  C. Rodriguez-Gonzalez,et al.  Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. , 2014, The Journal of antimicrobial chemotherapy.

[4]  F. Dromer,et al.  Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010 , 2014, Emerging infectious diseases.

[5]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  L. Fornecker,et al.  Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. , 2012, The Journal of antimicrobial chemotherapy.

[9]  J. Weston,et al.  Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. , 2011, The Journal of antimicrobial chemotherapy.

[10]  A. Thiébaut,et al.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.

[11]  L. Pagano,et al.  Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). , 2010, The Journal of antimicrobial chemotherapy.

[12]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  T. Calandra,et al.  Empirical antifungal therapy in neutropaenic cancer patients with persistent fever , 2007 .

[15]  A. Thiébaut,et al.  Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients , 2007 .

[16]  J. Burke,et al.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Baddley,et al.  Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. , 2005, Diagnostic microbiology and infectious disease.

[18]  J. Aguado,et al.  A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.